Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Cantor Fitzgerald

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “neutral” rating restated by equities researchers at Cantor Fitzgerald in a note issued to investors on Friday, Benzinga reports. They currently have a $925.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential downside of 3.34% from the company’s previous close.

A number of other brokerages also recently issued reports on REGN. BMO Capital Markets lifted their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Bank of America increased their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. Finally, Truist Financial restated a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $977.77.

Regeneron Pharmaceuticals Stock Up 2.1 %

REGN stock opened at $957.00 on Friday. The stock has a 50-day simple moving average of $943.75 and a two-hundred day simple moving average of $896.33. Regeneron Pharmaceuticals has a twelve month low of $684.80 and a twelve month high of $998.33. The firm has a market capitalization of $105.04 billion, a PE ratio of 28.27, a PEG ratio of 2.74 and a beta of 0.17. The company has a quick ratio of 4.94, a current ratio of 6.40 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $10.96 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals will post 38.86 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders sold a total of 10,095 shares of company stock worth $9,664,476 over the last quarter. 8.83% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. 9258 Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $207,000. Team Hewins LLC raised its stake in Regeneron Pharmaceuticals by 2.5% during the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 11 shares during the last quarter. Csenge Advisory Group boosted its holdings in Regeneron Pharmaceuticals by 12.3% in the first quarter. Csenge Advisory Group now owns 449 shares of the biopharmaceutical company’s stock worth $432,000 after acquiring an additional 49 shares in the last quarter. Signaturefd LLC grew its stake in shares of Regeneron Pharmaceuticals by 5.8% in the first quarter. Signaturefd LLC now owns 2,250 shares of the biopharmaceutical company’s stock worth $2,165,000 after acquiring an additional 124 shares during the last quarter. Finally, Catalina Capital Group LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $241,000. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.